Products for Research Use Only

SET-171

CAT: 0804-HY-168337Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-168337Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor that exhibits significant anticancer activity and lipid metabolism regulation by inhibiting liver pyruvate kinase (PKL) expression. In anticancer studies, SET-171 shows IC50 values of 8.82 μM and 2.97 μM against HepG2 and Huh7 cell lines, respectively, indicating high cytotoxicity. Additionally, in non-alcoholic fatty liver disease (NAFLD) -related studies, SET-171 significantly reduces triacylglycerol (TAG) levels and inhibits the expression of steatosis-related proteins. SET-171 holds promise for research on hepatocellular carcinoma (HCC) and NAFLD[1].
CAS Number
3052985-32-4
UNSPSC
12352005
Target
JNK; Pyruvate Kinase
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Metabolic Enzyme/Protease
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/set-171.html
Smiles
BrC1=CC=CC(NC(CN2CCC3=C(SC(NC(C4=CC=CC5=C4C=CC=C5)=O)=C3C#N)C2)=O)=C1
Molecular Formula
C27H21BrN4O2S
Molecular Weight
545.45
References & Citations
[1]Iqbal S, et al. Design and synthesis of novel JNK inhibitors targeting liver pyruvate kinase for the treatment of non-alcoholic fatty liver disease and hepatocellular carcinoma. Bioorg Chem. 2024 Jun;147:107425.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported